Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E5555 drug-drug interaction study with diltiazem in healthy volunteers
NL-OMON34620Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of atopaxar and diltiazem in coronary arteriosclerosis, acute coronary syndrome (ACS) and thrombosis (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Pharmacokinetics of E5555 and known metabolites, Pharmacodynamics: thrombin-induced platelet aggregation and 1 more. Started Oct 2010; status: active, not recruiting.
02
Drugs
atopaxardiltiazem
03
Conditions
coronary arteriosclerosisacute coronary syndrome (ACS)thrombosis
Beyond the preview
Go deeper on NL-OMON34620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34620.